Company / R&D Expense
Terns Pharmaceuticals, Inc. R&D Expense History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$70.1M
FY2024
5-year range
$28.0M / $70.1M
FY2020-FY2024
Trend
+10.4%
vs FY2023
Sector context
#161 of 208
Health Care
What the data says
Terns Pharmaceuticals, Inc.'s r&d expense of $70M is lower than 77% of companies in the Health Care sector (FY2024). R&D Expense has increased for 4 consecutive years, from $28M in FY2020 to $70M in FY2024.
Based on SEC 10-K filings.
$70M in FY2024 with a 3-year CAGR of +30.8%.
Improved from $40M to $70M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +30.8%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 208This company $70.1M Sector average $644.3M
▼
-89.1% below sector average
Key checks
Key Insights
- Terns Pharmaceuticals, Inc.'s r&d expense has grown for 4 consecutive years.
- 3-year CAGR of +30.8%, indicating consistent growth.
- In FY2024, r&d expense increased 10.4% year-over-year.
- Ranks #161 out of 208 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $70.1M | +10.4% |
| FY2023 | $63.5M | +60.3% |
| FY2022 | $39.6M | +26.5% |
| FY2021 | $31.3M | +11.7% |
| FY2020 | $28.0M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026